Improved control of nosocomial C. difficile transmission by daily use of an oxygen-releasing sporicidal disinfectant
AbstractContaminated surfaces contribute to transmission of C. difficile in the healthcare setting. The aim of the investigation was to assess the effectiveness of an environmental disinfection protocol consisting of daily use of the oxygen-releasing sporocide Oxygenon® Liquid (Antiseptica) in preventing nosocomial CDI, compared to daily surface disinfection with a quaternary ammonium compound-based product plus the oxygen-releasing sporicide Perform® (Schülke+) for targeted sporicidal environmental disinfection. In a pre-post single group study with patients of two internal medicine wards (A and B) between February 2008 and May 2011, we compared the CDI rate between the pre- and post-intervention phase by calculating the post-pre phase CDI rate-difference and preventable fraction. In a pre-post parallel groups study from August 2009 until May 2011, the post-pre phase CDI rate-difference of the experimental group (internal medicine ward B) was compared with the post-pre CDI rate-difference of a control group (general surgery department) by calculating the between-group difference in the post-pre CDI rate-difference. In the pre-post single group study, among patients ≥ 70 year olds, the post-pre phase CDI rate reduction of 14.0/10,000 bed-days was significant, and preventable fraction of CDI was 60.2% (95%CI: 15.6%-82.8%). The results of the pre-post parallel groups study suggested a superiority of the new environmental disinfection protocol at borderline significance. The post-pre CDI rate-difference in the experimental group was greater than the post-pre rate-difference in the control group by 10.4/10,000 bed-days. Using a sporicide for daily surface decontamination may be superior to targeted sporicidal disinfection in preventing nosocomial transmission of C. difficile.
Copyright conditions: Copyright on any research article in the International Journal of Infection Control (IJIC) is retained by the author(s). Authors grant IJIC permission to publish the article and identify itself as the original publisher. Authors also grant any third party the right to use the article freely as long as its integrity is maintained and its original authors, citation details and publisher are identified. IJIC conforms to the Creative Commons Attribution License (http://creativecommons.org) as terms and conditions of publishing research articles. In summary, anyone is free: • to copy, distribute, and display the work; • to make derivative works; • to make commercial use of the work; as long as: • the original author must be given credit; • for any reuse or distribution, it must be made clear to others what the license terms of this work are; • any of these conditions can be waived if the authors gives permission. Statutory fair use and other rights are in no way affected by the above. Authors' certification: In submitting a manuscript to IJIC, authors are requested to certify that: • They are authorized by their co-authors to enter into these arrangements. • They warrant, on behalf of themselves and their co-authors, that: o the article is original, has not been formally published in any other peer-reviewed journal, is not under consideration by any other journal and does not infringe any existing copyright or any other third party rights; o they are the sole author(s) of the article and have full authority to enter into this agreement and in granting rights to IJIC are not in breach of any other obligation. If the law requires that the article be published in the public domain, they will notify IJIC at the time of submission; o the article contains nothing that is unlawful, libellous, or which would, if published, constitute a breach of contract or of confidence or of commitment given to secrecy; o they have taken due care to ensure the integrity of the article.